Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Apyx Medical (APYX) over the last 15 years, with Q3 2025 value amounting to -$519000.0.

  • Apyx Medical's Cash from Investing Activities fell 23921.57% to -$519000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 9017.54%. This contributed to the annual value of -$722000.0 for FY2024, which is 11072.17% down from last year.
  • As of Q3 2025, Apyx Medical's Cash from Investing Activities stood at -$519000.0, which was down 23921.57% from -$265000.0 recorded in Q2 2025.
  • Over the past 5 years, Apyx Medical's Cash from Investing Activities peaked at $7.1 million during Q2 2023, and registered a low of -$519000.0 during Q3 2025.
  • In the last 5 years, Apyx Medical's Cash from Investing Activities had a median value of -$174000.0 in 2023 and averaged $181052.6.
  • In the last 5 years, Apyx Medical's Cash from Investing Activities plummeted by 178888.89% in 2021 and then skyrocketed by 187331.67% in 2023.
  • Over the past 5 years, Apyx Medical's Cash from Investing Activities (Quarter) stood at -$332000.0 in 2021, then soared by 57.23% to -$142000.0 in 2022, then surged by 34.51% to -$93000.0 in 2023, then tumbled by 163.44% to -$245000.0 in 2024, then tumbled by 111.84% to -$519000.0 in 2025.
  • Its Cash from Investing Activities was -$519000.0 in Q3 2025, compared to -$265000.0 in Q2 2025 and -$55000.0 in Q1 2025.